For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220228:nRSb1008Da&default-theme=true
RNS Number : 1008D Tata Steel Limited 28 February 2022
February 28, 2022
London Stock Exchange
London
Dear Madam, Sirs,
Sub: Execution of definitive agreement for acquisition of 90% equity
stake in Ceramat Private Limited by Tata Steel Advanced Materials Limited
("TSAML")
This is to inform you that, TSAML an indirect wholly owned subsidiary ("WOS")
of Tata Steel Limited, has, today, February 28, 2022, executed a Share
Purchase cum Shareholders' Agreement ("SPSHA") for acquisition of 90% equity
stake in Ceramat Private Limited ("CPL").
The relevant details with respect to the acquisition of 90% equity stake in
CPL are given in Annexure 1.
This disclosure is being made in compliance with Regulation 30 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015.
This is for your information and records.
ANNEXURE 1
SN. Particulars Details
1. Name of the target entity, details in brief such as size, turnover etc
Ceramat Private Limited ("CPL") was incorporated on November 2, 2021, for the
purpose of advanced ceramics with health care focus. CPL is jointly promoted
by
Mr. Sabyasachi Roy and Mr. Tushar Gothi.
As of date, CPL has not commenced operations.
2. Whether the acquisition would fall within related party transaction(s) and
whether the promoter/ promoter group/ group companies have any interest in the
entity being acquired? If yes, nature of interest and details thereof and No
whether the same is done at "arms-length"
3. Industry to which the entity being acquired belongs Bio-Ceramics
4. Objects and effects of acquisition (including but not limited to, disclosure Tata Steel Limited has identified Advanced Ceramics as one of the new
of reasons for acquisition of target entity, if its business is outside the materials for strategic growth. Within Advanced Ceramics, the first sector of
main line of business of the listed entity) choice is in medical materials owing to high growth potential and non-cyclical
nature. Tata Steel Limited aspires to setup a world class facility to produce
medical materials and use CPL as a special purpose vehicle for this purpose.
The facility shall focus on producing Hydroxyapatite - a calcium
phosphate-based ceramic used as bone replacement.
The promoter of CPL are amongst the very few with such proven capability.
5. Brief details of any governmental or regulatory approvals required for the
acquisition
None
6. Indicative time period for completion of the acquisition Within 60 days from the date of signing of the agreement
7. Nature of consideration - whether cash consideration or share swap and details Cash
of the same
8. Cost of acquisition or the price at which the shares are acquired ₹90,000/-
9. Percentage of shareholding / control acquired and / or number of shares 90% equity shares of CPL
acquired
10. CPL was incorporated on
November 2, 2021 in India, for the purpose of advanced ceramics with health
Brief background about the entity acquired in terms of products/line of care focus. CPL is jointly promoted by
business acquired, date of incorporation, history of last 3 years turnover,
Mr. Sabyasachi Roy and Mr. Tushar Gothi. Mr. Sabyasachi Roy is a ceramic
country in which the acquired entity has presence and any other significant technologist and an entrepreneur and
information (in brief)
Mr. Tushar Gothi has been associated with ceramic business for 16 years.
As on date, CPL has not commenced operations.
CPL promoters have the core competence of various oxide ceramic composition
manufacturing through process routes like slip casting, gel casting, powder
compaction, spray drying and vibro-casting instrumental in advanced ceramics
manufacturing.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END AGRDZGZZNRKGZZM